A total of 79 GC patients with centrally confirmed HER2 positive disease on biopsy after progression to first-line trastuzumab-containing regimen were treated with T-DXd at 6.4 mg/kg every 3 weeks. This evidence concerns the gene ERBB2 and gastric cancer.